Bioxyne (ASX:BXN) said its unit Breathe Life Sciences UK has received funding of about AU$1.7 million from South of Scotland Enterprise to establish a medicinal cannabis manufacturing and distribution facility in the UK, according to a Monday filing with the Australian bourse.
Application for the required licences will be completed in 2026, the filing said.
Shares of the company fell 5% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.